Tuberculosis, Endocrine Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Tuberculosis, Endocrine. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Tuberculosis, Endocrine receives a directional score of 71/100, combining unmet need (83/100), competitive intensity (47/100) and market attractiveness (69/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Infection of the ENDOCRINE GLANDS with species of MYCOBACTERIUM, most often MYCOBACTERIUM TUBERCULOSIS.

The reproducible record is Patsnap disease ID 7ac017786a344b738a34a4788e9df472 and MeSH identifier D014383. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Global tuberculosis report 2024 3. Main findings and messages

TB can affect anyone, regardless of age or sex (Fig. 4). The highest burden is in adult men (aged ≥15 years13), with an estimated 6.0 million cases (95% UI: 5.5–6.4 mil- lion) in 2023, equivalent to 55% of the estimated total. There were an estimated 3.6 million cases (95% UI: 3.3–3.9 million) among adult women (aged ≥15 years), equivalent to 33% of the estimated total; and 1.3 mil- lion cases (95% UI: 1.2–1.3 million) among children and young adolescents (aged 0–14 years), equivalent to 12% of the estimated total.14 The higher share of TB cases among men is consistent with evidence from nation- al TB prevalence surveys, which show that TB disease affects men more than women, and that gaps in case detection and reporting are higher among men (17). Among all incident cases of TB in 2023, 6.1% were 13 The age groups for which WHO collects case notification data and produces estimates of disease burden are 0–4, 5–14, 15–24, 25–34, 35–44, 45–54, 55–64 and ≥65 years. 14 The three numbers do not sum to the overall best estimate of 10.8 million due to rounding. FIG. 4 Global estimates of TB incidence disaggregated by age group and sex (female in purple; male in orange), 2023 0–4 5–14 15–24 25–34 35–44 45–54 55–64 ≥65 Age group (years) people living with HIV; this proportion has been steadi- ly declining for several years. The proportion of people with a new episode of TB who were living with HIV was highest in countries in the WHO African Region, exceed- ing 50% in parts of southern Africa. The severity of national TB epidemics – in terms of the number of incident (new) TB cases p

Review source

Epidemiology evidence 2: Global tuberculosis report 2025 3. Main findings and messages

Geographically, most people who developed TB in 2024 were in the WHO regions of South-East Asia (34%), the Western Pacific (27%) and Africa (25%),2 with small­ er proportions in the Eastern Mediterranean (8.6%), the Americas (3.3%) and Europe (1.9%).3 The 30 high TB burden countries4 accounted for 87% of all estimated incident cases worldwide, with eight of these countries (Fig. 3) accounting for two thirds (67%) of the glob­ al total: India (25%), Indonesia (10%), the Philippines (6.8%), China (6.5%), Pakistan (6.3%), Nigeria (4.8%), the Democratic Republic of the Congo (3.9%) and Bangla­ desh (3.6%). The top five countries accounted for 55% of the global total. TB can affect anyone, regardless of age or sex (Fig. 4). The highest incidence is in adult men (aged ≥15 years5), with an estimated 5.8 million cases (95% UI: 4.2–7.4 mil­ lion) in 2024, equivalent to 54% of the estimated total. There were an estimated 3.7 million cases (95% UI: 2.7–4.7 million) among adult women (aged ≥15 years), equivalent to 35% of the estimated total; and 1.2 mil­ 2 Regional shares for the WHO South-East Asia and Western Pacific regions differ from those published in previous reports, following the reassignment of Indonesia to the WHO Western Pacific Region (see above). 3 Regional percentages do not sum to 100 because of rounding. 4 See Annex 3. 5 The age groups for which WHO collects TB case notification data and produces estimates of disease burden are 0–4, 5–14, 15–24, 25–34, 35–44, 45–54, 55–64 and ≥65 years. FIG. 5 Estimated TB incidence rates at country level, 2024 lion cases (95% UI: 0.9

Review source

Epidemiology evidence 3: Eurosurveillance - Volume 30, Issue 39, 02 October 2025 Conflict of interest

1. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 1976;19:1-63. PMID: 823803 2. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131-8. https://doi-org.sutd.idm.oclc.org/10.1093/ oxfordjournals.aje.a121593 PMID: 4810628 3. Brodhun B, Altmann D, Hauer B, Kröger S, Haas W. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2022. [Report on the Epidemiology of Tuberculosis in Germany for 2022]. Berlin: Robert-Koch-Institut; 2023. German. Available from: https://www.rki.de/DE/Themen/Infektionskrankheiten/ Infektionskrankheiten-A-Z/T/Tuberkulose/Archiv_Berichte_TB_ in_Dtl_tab.html 4. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928-52. https://doi. org/10.1183/09031936.00214014 PMID: 25792630 5. European Centre for Disease Prevention and Control (ECDC). Programmatic management of latent tuberculosis infection in the European Union. Stockholm: ECDC; 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/ programmatic-management-latent-tuberculosis-infection- european-union 6. Erkens CG, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J. 2010;36(4):925-49. https://doi. org/10.1183/09031936.00201609 PMID: 20889463 7. Velen K, Shingde RV, Ho

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Tuberculosis, Endocrine, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Tuberculosis, Endocrine thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor is PTH1R, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 2 registered studies.

• ChiCTR2200065345 — Retrospective study of treatment patterns and clinical outcomes in patients with severe tuberculosis; Not yet recruiting; Not Applicable; sponsor Wuhan Xiehe Hospital Tower, Huazhong University of Science Tongji Hospital, Tongji Medical College; enrollment 900.
• ISRCTN12506117 — Malnutrition and diabetes in tuberculosis treatment programs in the Philippines; Completed; Not Applicable; sponsor University of Nagasaki; enrollment 750.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate PTH1R relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Tuberculosis, Endocrine merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Tuberculosis, Endocrine is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.